Concernant les diverses indemnités de départs convenues au bénéfice des dirigeants, bien que les montants maximum des indemnités soient en ligne avec le plafond de 12 mois de rémunération salariale (fixe + bonus annuel) fixé par Proxinvest, les motifs donnant droit au versement de celles-ci ne respectent pas la politique de Proxinvest qui en limite le versement à la seule hypothèse d’un départ contraint et lié à changement de contrôle.
La résolution 17 relative à l’approbation des principes de détermination des éléments de rémunération des dirigeants pour l’exercice 2017 ne peut être soutenue en raison d’un manque de transparence de la société.
Par ailleurs, le conseil est indépendant à 85,71% selon Proxinvest, ce qui est satisfaisant. Ainsi, Proxinvest soutient le renouvellement, la ratification et la nomination des administrateurs proposés aux résolutions 19, 20 et 21.
Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
FFP is due to report its NAV at end-2018 on 18 March. We estimate this at € 148 per share, down 5% over 2018. Since the start of 2019, we estimate the rebound at 13% to € 167 per share. Buy recommendation maintained to benefit from dual leverage on the valuation: growth in NAV (the track record is excellent) and narrowing of the discount (historically high level of 43%). Target price lowered to € 131 vs € 136 previously. - ...
General: Supervisory Board member Prof. Dr. Theo Siegert is a member of the Adivsory Committee of DSW, the local partner of ECGS. This report has been prepared using standard ECGS guidelines. Item 1: Unlike at German stock corporations, shareholders of a KGaA are legally required to vote on the annual accounts. Item 5: In financial year 2018, the Supervisory Board of Henkel Management AG, in line with recommendations of the Shareholders' Committee's Human Resources Subcommittee, decided to adopt various changes to the Management Board members' remuneration system, applicable as of financial ...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.